Little House Capital LLC Has $2.73 Million Holdings in Eli Lilly and Company (NYSE:LLY)

Little House Capital LLC increased its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 39.3% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 3,503 shares of the company’s stock after buying an additional 988 shares during the quarter. Eli Lilly and Company accounts for approximately 0.9% of Little House Capital LLC’s holdings, making the stock its 29th largest holding. Little House Capital LLC’s holdings in Eli Lilly and Company were worth $2,725,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Lipe & Dalton acquired a new stake in shares of Eli Lilly and Company in the 4th quarter valued at about $26,000. Core Wealth Advisors Inc. raised its stake in shares of Eli Lilly and Company by 188.2% in the 4th quarter. Core Wealth Advisors Inc. now owns 49 shares of the company’s stock valued at $29,000 after purchasing an additional 32 shares during the period. Tidemark LLC bought a new position in shares of Eli Lilly and Company in the 4th quarter valued at about $29,000. Frank Rimerman Advisors LLC bought a new position in shares of Eli Lilly and Company in the 4th quarter valued at about $37,000. Finally, St. Johns Investment Management Company LLC grew its holdings in shares of Eli Lilly and Company by 123.3% in the 4th quarter. St. Johns Investment Management Company LLC now owns 67 shares of the company’s stock valued at $39,000 after acquiring an additional 37 shares in the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Trading Up 1.0 %

Shares of LLY stock opened at $914.37 on Tuesday. The firm has a 50 day moving average price of $814.40 and a two-hundred day moving average price of $740.86. The company has a quick ratio of 1.03, a current ratio of 1.35 and a debt-to-equity ratio of 1.90. The company has a market capitalization of $869.03 billion, a PE ratio of 134.66, a price-to-earnings-growth ratio of 1.97 and a beta of 0.41. Eli Lilly and Company has a 12-month low of $434.34 and a 12-month high of $916.83.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Monday, May 6th. The company reported $2.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.53 by $0.05. Eli Lilly and Company had a net margin of 17.08% and a return on equity of 56.98%. The firm had revenue of $8.77 billion during the quarter, compared to the consensus estimate of $8.94 billion. During the same period last year, the business posted $1.62 earnings per share. The business’s revenue for the quarter was up 26.0% compared to the same quarter last year. As a group, analysts predict that Eli Lilly and Company will post 13.76 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 10th. Stockholders of record on Thursday, August 15th will be given a $1.30 dividend. The ex-dividend date of this dividend is Thursday, August 15th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 0.57%. Eli Lilly and Company’s payout ratio is 76.58%.

Insider Activity

In other news, major shareholder Lilly Endowment Inc sold 2,052 shares of Eli Lilly and Company stock in a transaction that occurred on Tuesday, May 28th. The shares were sold at an average price of $809.00, for a total value of $1,660,068.00. Following the completion of the sale, the insider now directly owns 98,554,195 shares in the company, valued at $79,730,343,755. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. In other Eli Lilly and Company news, EVP Johna Norton sold 7,056 shares of the business’s stock in a transaction on Monday, June 3rd. The shares were sold at an average price of $819.38, for a total transaction of $5,781,545.28. Following the sale, the executive vice president now owns 25,428 shares of the company’s stock, valued at $20,835,194.64. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, major shareholder Lilly Endowment Inc sold 2,052 shares of the business’s stock in a transaction on Tuesday, May 28th. The stock was sold at an average price of $809.00, for a total transaction of $1,660,068.00. Following the sale, the insider now directly owns 98,554,195 shares in the company, valued at approximately $79,730,343,755. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 791,145 shares of company stock worth $673,704,508. Corporate insiders own 0.13% of the company’s stock.

Analyst Upgrades and Downgrades

LLY has been the subject of several analyst reports. The Goldman Sachs Group raised their price objective on Eli Lilly and Company from $650.00 to $723.00 and gave the company a “neutral” rating in a report on Thursday, April 11th. Cantor Fitzgerald restated an “overweight” rating and issued a $885.00 price objective on shares of Eli Lilly and Company in a report on Monday. Bank of America restated a “buy” rating and issued a $1,000.00 price objective on shares of Eli Lilly and Company in a report on Monday, June 24th. Citigroup raised their price objective on Eli Lilly and Company from $675.00 to $895.00 and gave the company a “buy” rating in a report on Tuesday, April 2nd. Finally, JPMorgan Chase & Co. raised their price objective on Eli Lilly and Company from $850.00 to $900.00 and gave the company an “overweight” rating in a report on Wednesday, May 1st. Three research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company. Based on data from MarketBeat.com, Eli Lilly and Company presently has an average rating of “Moderate Buy” and an average price target of $812.72.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.